Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of acute myeloid leukemia
3.2.1.2 Advancement in research and technology
3.2.1.3 Surging government initiative and policy
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness and knowledge
3.2.2.2 High cost associated with treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter’s analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Myeloblastic leukemia
5.3 Myelomonocytic leukemia
5.4 Promyelocytic leukemia
5.5 Monocytic leukemia
5.6 Other leukemia types
Chapter 6 Market Estimates and Forecast, By Treatment Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Chemotherapy
6.2.1 Anti-metabolites
6.2.2 Alkylating agents
6.2.3 Anthracycline drugs
6.2.4 Other chemotherapy types
6.3 Targeted therapy
6.4 Immunotherapy
6.5 Other treatment types
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Parenteral
7.3 Oral
Chapter 8 Market Estimates and Forecast, By End-user, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals & clinics
8.3 Specialty centers
8.4 Homecare settings
8.5 Ambulatory care centers
Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Astellas Pharma Inc.
10.2 Bristol Myers Squibb Company
10.3 Celgene Corporation
10.4 Daiichi Sankyo Company, Limited
10.5 Jazz Pharmaceuticals plc
10.6 Novartis AG
10.7 Otsuka Pharmaceutical Co., Ltd.
10.8 Partner Therapeutics, Inc.
10.9 Pfizer Inc.
10.10 Rigel Pharmaceuticals, Inc.
